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Objective: To develop and evaluate tools for the audit of spas-
ticity management with botulinum toxin.
Design: Audit tools to assess the organisation of services and 
process of care were developed with a consensus process. 
The tools were piloted across 8 services using a retrospective 
case note audit. Inter-rater reliability was assessed, using 
percentage agreement and kappa scores. Clinicians involved 
in the pilot were surveyed and qualitative feedback was ana-
lysed. 
Results: Eight services (100%) completed service Organisa-
tion tools and 7 (88%) returned process of Care tools. One 
hundred sets of clinical records were audited, with 34 used 
to assess inter-rater reliability. Eleven items on the process 
of care tool demonstrated a good degree of inter-rater agree-
ment, but 6 require further development. In the qualitative 
analysis clinicians stated that the tools captured indicators 
of quality, and that they would use them again. They recom-
mended that patient satisfaction was included as a measure 
of quality. The audit has been used practically in the pilot 
services to provide an impetus for quality improvement.
Conclusions: The majority of the audit questions showed a 
good level of reliability, and clinician feedback supports face 
validity but a larger scale evaluation is required.
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INTRoduCTIoN
There is an absence of data to indicate the prevalence of 
spasticity generally, but studies estimate that up to 40% of 
stroke survivors are affected (1), and up to 85% of people with 
multiple sclerosis (2). Currently it is recognised that optimal 
treatment should be multidisciplinary and includes physical 
interventions and medications such as botulinum toxin (3).
In January 2009, the Royal College of Physicians, uK 
published national guidelines for managing spasticity with 
botulinum toxin (4). The guidelines contain recommendations 
that cover the organisation of services, and the process of care. 
The original guidelines were published without tools to assess 
the extent of their implementation. The aim of this project was 
to use a structured process to develop and evaluate audit tools 
for this purpose. 
MeThodS
The uK healthcare Quality Improvement Partnership (5) has devel-
oped a structured framework to ensure the quality of clinical audit. 
This framework includes a step wise process to agreeing standards 
with all stakeholders, and ensuring that data collection and analysis 
are reliable. The framework was adopted to ensure a robust approach 
to the development of these tools (Fig. 1).
The first step of the process was to agree the draft tools through a 
consensus process with clinicians and service users. Nine standards 
relating to service organisation and 17 related to process of care were 
drawn from the national guidelines (the remainder related to research 
recommendations). The standards and questions for their audit were 
sent to the lead clinicians of the 8 spasticity services in the region with 
a request for feedback. This indicated that all the clinicians agreed 
with the standards and felt the tools had face validity in measuring 
achievement against the standards. Service user views were ascertained 
via a broader project on patient and public involvement in spasticity 
services. Twenty-nine people, who had attended a local clinic, were 
asked to indicate areas of service provision that were important to them. 
Seventeen (59%) people responded, and highlighted the importance of 
having the opportunity to discuss prognosis and different treatments, 
and receiving information about self management and exercise (6). 
These comments gave further support to the standards and draft tools 
(Appendix I). 
The service organisation tool included aspects of team working, 
training, access to equipment, and links with other services. The proc-
ess of care tool was designed to audit clinical records and consisted 
of 17 items related to assessment, consent, goal-planning, treatment, 
information provision and aftercare. Audit questions were phrased so 
that answers were ‘Yes’ or ‘No’ depending on whether the standard 
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Fig. 1. Process of development and evaluation of tools. 
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had been met, with a ‘No, but’ category to allow for situations when 
the standards may not apply. The draft process of care tool was tested 
with clinicians working in rehabilitation in the developing hospital, 
and findings were used to draft some written advice for completion of 
the tool, prior to a regional audit across the 8 centres. each service was 
then asked to audit at least 15 sets of records and to audit 5 of these 
twice using different auditors, working independently. 
Following return of the tools, the data were entered into an excel 
spreadsheet and the agreement between auditors and kappa scores 
calculated for each audit item (7). each clinician who had taken part 
in the audit received a questionnaire to ascertain qualitative feedback 
to the use of the tools with a mix of open and closed questions. The 
questions are shown in Table I. written qualitative responses were 
entered into a framework and analysed (8). 
ReSulTS
All 8 services returned completed copies of the service or-
ganisation tool. Seven services completed process of care 
tools, with a total of 100 sets of case records audited. Four 
services used two independent auditors to assess a total of 34 
sets of records. 
Statistical analysis
The full results of the analysis are shown in Table II. Agreement 
between independent raters varied from 41% to 100% over the 
set of questions. Audit questions where there was a high level 
of agreement included recording of product, dose and dilution, 
agreeing goals, and planning long-term care. Areas where there 
was lower agreement included the recording of discussion of 
risks, follow up reviews, and information provision. where pos-
Table I. Questions to structure qualitative feedback
• Did you agree with the standards used for the audit?
• Were the tools easy to complete?
• Do you feel that the tools captured indicators of quality in spasticity 
management with botulinum toxin? If not, what was missing?
• Was there anything else we should have included on the tools?
• Has the process been helpful?
• Would you use the audit again?
• Is there anything else you would like to feedback?
Table II. Summary of statistical analysis and decision making process
Question
% agreement 
between raters Kappa coefficient
Confidence 
interval Kappa rating Comments decision
Is there a record of patient and carer 
expectations?
70 0.02 0–0.53 Poor Moderate agreement
high variation
This question needs 
further development
Is there a record of consent 88 0.64 0.29–0.97 good high agreement
high variation
Include in final draft
did patient receive information on 
risks of treatment?
67 0.26 0–0.61 Fair Moderate agreement
high variation
This question needs 
further development
Is there a formal assessment of 
spasticity?
82 0.4 0–0.83 Fair high agreement
Moderate variation
Include in final draft
Is there a functional goal of 
treatment?
88 b NA a high agreement
low variation
Include in final draft
Is an outcome measure completed? 100 1 1–1 Perfect high agreement
Moderate variation
Include in final draft
Is the product used recorded? 100 b NA a high agreement
No variation
Include in final draft
Is the dose given recorded? 100 b NA a high agreement
No variation
Include in final draft
Is dilution of dose recorded? 97 0.92 0.77–1 very good high agreement
high variation
Include in final draft
has a follow up treatment plan been 
identified?
88 0.54 0.12–0.96 Moderate high agreement
Moderate variation
Include in final draft
was there a therapy review at 7–14 
days post injection?
41 0.15 0–0.39 Poor low agreement
high variation
This question needs 
further development
was the patient reviewed at 4–6 
weeks post injection?
61 0.39 0.13–0.64 Fair Moderate agreement
high variation
This question needs 
further development
was the patient reviewed at 3–4 
months to plan future treatment?
71 b NA a Moderate agreement
low variation
 Include in final draft
Is there an evaluation of goals? 85 0.41 0–0.87 Moderate high agreement
high variation
Include in final draft
Is there an evaluation of outcomes? 70 0.36 0.03–0.69 Fair Moderate agreement
high variation
This question needs 
further development
was information given to support 
self management?
61 0.13 0–0.51 Poor Moderate agreement
high variation
This question needs 
further development
Is there a plan for future 
management?
88 0.29 0–0.94 a high agreement
low variation
Include in final draft
aexample of kappa paradox.
bKappa scores were unable to be calculated due to very low, or no variation, within the responses.
J Rehabil Med 44
560 R. Allison and K.M. Knapp
sible, kappa scores were calculated for each question. generally, 
a kappa of +1.00 indicates perfect agreement, whereas a value 
of zero indicates agreement no better than chance (7). 
There were 5 questions where kappa values could not be 
calculated as there was insufficient variance in the range of 
responses of auditors (this typically occurred when there was 
high agreement between raters but little variation across the 
‘Yes’, ‘No’ or ‘No, but’ categories). viera & garrett (10) and 
Cicchetti & Feinstein (11) have highlighted this difficulty and 
suggest that interpretation of reliability results needs to take 
account of both percentage of rater agreement, and kappa 
scores, which was the approach taken in this case. An audit 
question was considered suitable for the final tool if the kappa 
statistic was classified as good, very good, or perfect. Questions 
were also accepted if the kappa value was fair or could not be 
calculated but the percentage agreement between raters was at 
least 70%, with moderate or low variation across the range of 
responses. Table II summarises these results. It should be noted 
that even when kappa values are high, confidence intervals are 
large, due to the relatively small sample size. 
The analysis identified that 11 questions on the tool dem-
onstrated a fair degree of agreement and reliability. Six of the 
questions were identified as requiring further work before they 
could be included in a final draft of the tools. These questions 
related to discussing patient expectations and risks, evaluating 
outcomes, giving information to support self management, and 
follow-ups. These areas are fairly subjective areas to grade with 
audit, and it is likely that more explicit written advice is needed 
to support the tools. The statistical analysis was supplemented 
by the review of qualitative feedback from clinicians. 
Qualitative feedback
eleven clinicians who had completed the audit tools were sent 
a follow-up questionnaire. Seven of them (64%) returned writ-
ten comments and all of them indicated that they agreed with 
the standards used, had found the tools easy to complete and 
would use them again. All the clinicians indicated that they 
felt the tools captured indicators of quality, a statement that 
supports the face validity of the tools. 100% also expressed 
that they had found the process to be useful and gave com-
ments to explain this:
‘The process was useful as it has highlighted the need for stand-
ardised documentation and written information.’ Auditor 7
Four of the clinicians made comments about the need for feed-
back from patients or carers, as described in this example:
‘I thought it captured the structure of the clinic but not 
really the quality from a patient or carers perspective.’ 
Auditor 1
one of the clinicians suggested that the audit tools needed to 
include a measure of patient or carer experience, but this may 
be difficult to achieve within an audit of records. An alterna-
tive may be for the audit tools to form one measure of quality 
assurance, but for this to also include a measure of patient 
and carer satisfaction. This could be particularly useful given 
the difficulty ensuring the reliability of responses to questions 
about some of the aspects of care involving discussion with 
patients such as expectations, risks of treatment, and infor-
mation provision, and given that the service users surveyed 
highlighted the importance of these areas. 
dISCuSSIoN
To the best of our knowledge, this has been the first project to 
develop and evaluate tools for audit of the national guidelines 
for spasticity management with botulinum toxin. The tools have 
been developed with input from both clinicians and service users, 
and have been piloted across all services within the Peninsula 
area. They not only provide a unique opportunity to observe care 
delivered at a regional level, but also allow individual providers 
to review their own performance in the local management of 
spasticity. Several of the clinics included in the pilot have used 
the data obtained to help evaluate and further develop services. 
one, for example, instigated a piece of work with service users 
and carers to develop written information to support self man-
agement after the audit highlighted the lack of this. 
Limitations of the study
Although results have been generally positive, this pilot has 
been small and a larger scale test of the final draft tools will be 
necessary to gain assurance regarding validity and reliability. 
Results from the statistical analysis demonstrated the para-
dox that can occur when calculating kappa scores on samples 
when there is a limited distribution of responses. A larger pilot 
may ameliorate this occurrence and produce more conclusive 
results, although, if the variation in responses remains low, 
kappa may not be a helpful method for statistical analysis.
Qualitative feedback was given by 64% of the clinicians in-
volved and it could be argued that those who felt most positively 
are more likely to have responded. The qualitative questions that 
were sent to clinicians were few in number and mostly closed. 
The initial comments support the face validity of the tools but a 
greater depth of feedback could be achieved through either the use 
of a longer survey with more open questions, or a focus group.
In conclusion, the purpose of this project was to develop multi 
disciplinary audit tools for spasticity management with botulinum 
toxin. draft tools were developed and piloted, using consensus 
techniques with input from clinicians and service users, and early 
piloting with a particular emphasis on reliability. eleven of the 
questions on the draft tools showed a good level of reliability, and 
clinician feedback supports the face validity. The tools are able to 
be used practically as part of the audit cycle to improve quality. 
Six of the questions on the tools need further work to support their 
reliability, and a larger pilot of the tool is ultimately required. The 
process highlighted the need for service user feedback as well as 
clinical audit as a component of a quality account.
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APPeNdIx I. Management of spasticity with botulinum toxin (bTx)
Patient identifier: Yes No No/but
Tool for audit of process of care. (To complete one per patient)
1. Is there a record of patient and carer expectations?    
2. Is there a record of consent?  
3. Did patient receive information on risks of treatment?    
4. Is there a formal assessment of spasticity?  
5. Is there a functional goal of treatment?  
6. Is an outcome measure completed prior to treatment?  
7. Is the product used recorded?  
8. Is the dose given recorded?  
9. Is dilution of dose recorded?  
10. Has a follow up treatment plan been identified?  
11. Was there a therapy review at 7–14 days post injection?  
12. Was the patient reviewed at 4–6 weeks post injection?  
13. Was the patient reviewed at 3–4 months to plan future treatment?  
14. Is there an evaluation of goals?  
15. Is there an evaluation of outcomes?  
16. Was information given to support self management?    
17. Is there a plan for future management?    
Tool for audit of service organization. (To complete one per service identified)
1. Is there a co-ordinated multidisciplinary team for managing spasticity?  
1a. If so, which professions typically attend clinics:
2. has the injecting clinician completed the following training requirements stipulated by the national 
guidelines (tick all that apply):  
a) Attendance on botulinum toxin training course (to include a formal certificate) approved by the relevant 
college.  
b) observation of the assessment of and injection technique in at least 5 patients with arm and 5 patients with 
leg spasticity related problems.  
c) Ability to use the relevant equipment, e.g. electromyography (eMg), nerve stimulation or ultrasound.  
3. has the injecting clinician(s) been involved in clinical professional development for this intervention in 
the past year?
 
4. Does this clinic provide training to other clinicians to develop skills in assessment and management?  
5. If so, do new clinicians in training complete the following training requirements stipulated by the national 
guidelines (tick all that apply):  
a) Attendance on BT training course (to include a formal certificate) approved by the relevant college.  
b) observation of the assessment of and injection technique in at least 5 patients with arm and 5 patients with 
leg spasticity related problems.  
c) Ability to use the relevant equipment eg eMg, nerve stimulation or ultrasound.  
6. Is there access to EMG/ muscle stimulation equipment if required?  
7. does the service have pathways of care for those with very complex disability including referral to:  
a) Intrathecal baclofen service.  
b) orthopaedic surgery.  
8. Does the service routinely provide written information to patients and carers on managing spasticity?  
9. If so, please indicate if this information is produced by the service or sourced externally.
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